The Global Chronic Kidney Disease Drugs Market Size is estimated to expand rapidly in coming years, at a CAGR of 3.60% from 2018 to 2025. In 2017, the global market valuation was USD 11.5 billion, and it is anticipated to be greater than USD xx.xx billion by 2025.
Global Market Growth Opportunities (Revenue, Growth) By 2017-2025
Chronic kidney disease, otherwise chronic kidney failures results in the lowering down the function or sometimes failure of kidneys. Wastes and excessive fluids filtered by the kidney are thereby excreted through urine. However, if these fluids reach dangerous levels, wastes and electrolytes are built into the body which may result in the gradual loss of kidney functioning. To retrieve the kidney functioning, numerous drugs are used such as swell treatment drugs, calcium channel bloggers, beta bloggers, and several others. In extreme cases such as kidney failure can be treated by kidney transplantation or artificial filtering. The global chronic kidney disease drugs market is anticipated to grow over a noticeable CAGR over the projected period owing to the rising prevalence of diabetic patients coupled with increasing obesity across the globe.
The global chronic kidney disease drugs market size continues to increase at a significant rate, majorly driven by growing number of patients suffering from chronic kidney disease and the rising need for proper treatments in order to improve the quality of life for every patient. The growing number of elderly populations who are vulnerable to diseases due to poor immunity, such as diabetes, cardiovascular disorders, and neurological conditions, is another major factor behind the growth of this market. According to Insights and Reports, more than 2 million people across the globe are currently receiving treatment with dialysis or kidney transplant in order to stay alive. However, intense competition from several biosimilars and rising number of generic drugs is a major constraint to the global chronic kidney disease drugs market size.
Drug Type Insights: Calcium channel blockers (CCB) segment is anticipated to dominate the global chronic kidney disease drugs market, majorly attributed by the increasing anti-hypertensive capacity in the CCB which aims to protect the renal damage. During the treatment process of chronic kidney diseases, antihypertensive drugs try to maintain the levels of blood pressure in the body. Therefore, the use of CCB may contribute significant growth to the global chronic kidney disease drugs market size over the projected period.
The global chronic kidney disease drugs market is divided into regions that are North America - U.S, Canada, Other) (Asia-Pacific -India, Japan, China, Australia, Other) (Europe - UK, Russia, France, Brazil, Other) (Middle East and Africa. Every region analysis details in sense of growth, revenue, volume, challenges, and opportunities with the regional and global key players. In terms of region wise study, North America dominated the global chronic kidney disease drugs market size, followed by Europe. Presence of advanced technology and the strong economic condition has resulted in the dominance of the North America chronic kidney disease drugs market. Concerns regarding the rise in the number of the obese and diabetic population are also expected to boost this regional market in the near future. In addition to this changing healthcare reimbursement environment and an increase in funding by different private organizations government agencies and in the healthcare system is resulting to the rise in the demand for CKD drugs. According to the U.S government health agency, the health spending in the U.S. is expected to rise by 5.3% in 2018 owing to the rising prices of the drugs and other medical goods.
Global Chronic Kidney Disease Drugs Market Size, Share Analysis By Region 2017
Asia Pacific chronic kidney disease drugs market size will witness the fastest growth rate during the forecast period, owing to the rising number of incidences suffering from diabetes and hypertension. According to the International Diabetes Federation estimates, in India, there were over 72.1 million diabetic patients in India, which is approximately 8.8% of the total population. The rising prevalence of diabetes among the population in this region may further lead to a significant rise in diabetic cases, which in turn might trigger the Asia Pacific chronic kidney disease drugs market share over the projected period.
Global Chronic Kidney Disease Drugs Market Study Objective
1. To forecast the market size of chronic kidney disease drugs market, along with describing and defining the market, in terms of volume and revenue.
2. Market analysis and forecast of chronic kidney disease drugs market on the basis of region, substrate and application or end-use industry.
3. To analyze and elaborate significant factors that will have major impact on the growth of chronic kidney disease drugs market, such as drivers, restraints, challenges and opportunities.
4. Regional analysis of chronic kidney disease drugs market, to induce market size of five global major regions, which include, Europe, North America, South America, Middle East & Africa and Asia Pacific.
5. Strategic analysis of micromarkets, in terms of individual prospects, opportunities, growth trends and their involvement in overall market.
6. To provide detailed analysis of competitive and strategic developments in the chronic kidney disease drugs market like new product launch, partnership & agreement, investment & expansion, and company merger & acquisitions.
7. Analysis of market opportunities for stakeholders, in order to provide a competitive landscape for global market players.
8. To profile major market players, and to analyze their market shares and essential competencies comprehensively.
Bottom-up and top-down are two main approaches that were taken into account to anticipate and validate the market size of chronic kidney disease drugs market, and to reach the anticipated market size of several dependent submarkets. The research and study involved massive utilization of secondary data sources, several directories, private and government websites, and authentic databases, to collect or gather market-oriented as well as technical information for the study of chronic kidney disease drugs market commercially.
Global chronic kidney disease drugs market is highly competitive and has numerous numbers of players. Some of the major players in this market include GlaxoSmithKline plc, Johnson & Johnson, Keryx Biopharmaceuticals Co. Ltd., and Pfizer among others. In May 2018, Keryx Biopharmaceuticals Co. Ltd. revealed the trial data of the treatment of CKD with ferric citrate. Data suggested that 76 of 133 patients accomplished nine months of the trial, 30 patients started with renal replacement therapy, 16 patients were terminated, 8 patients received the transplantation whereas 3 patients died during the trials.
Global Chronic Kidney Disease Drugs Market Study Report Offer You!
The global market study report gives an idea about market size, share, stock, equity, investment and total price analysis. Also, the report provides comprehensively industry insights with all major factors such as market credit, allocation, demand, distribution, market scope, key players, end user & applications, provisions, livestock, commodities and industry economics analysis, future growth & forecast. The global market report includes all depth data like pre-market emphasis, market survey, market investment, industry advice, portfolio, finance, access, trade, market exploration, industry review and market predication & projection to develop effective strategies for optimizing their market position.
Save Your Time
Wide Range of Reports
World Class Market Research
100% Customer Satisfaction
24/7 Customer care Support